Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Vernon

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 14, 2004
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapyMarc Weiner, Naomi Bock, Charles A Peloquin, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrationsMarc Weiner, Charles Peloquin, William Burman, et al.
JAMA Network Open|January 20, 2022
In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority TrialJoseph Burzynski, Joan M Mangan, Chee Kin Lam, et al.
American Journal of Respiratory and Critical Care Medicine|May 6, 2006
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosisWilliam J Burman, Stefan Goldberg, John L Johnson, et al.
Annals of the American Thoracic Society|March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatmentCraig M Hales, Charles M Heilig, Richard Chaisson, et al.
Contemporary Clinical Trials|April 2, 2023
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentineNigel A Scott, Claire Sadowski, Andrew Vernon, et al.
Lancet (London, England)|September 21, 2002
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialDebra Benator, Mondira Bhattacharya, Lorna Bozeman, et al.
Annals of the American Thoracic Society|February 3, 2018
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere TrialsRuth N Moro, Nigel A Scott, Andrew Vernon, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman, John L Johnson, Stefan Goldberg, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
American Journal of Respiratory and Critical Care Medicine|February 14, 2004
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapyMarc Weiner, Naomi Bock, Charles A Peloquin, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrationsMarc Weiner, Charles Peloquin, William Burman, et al.
JAMA Network Open|January 20, 2022
In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority TrialJoseph Burzynski, Joan M Mangan, Chee Kin Lam, et al.
American Journal of Respiratory and Critical Care Medicine|May 6, 2006
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosisWilliam J Burman, Stefan Goldberg, John L Johnson, et al.
Annals of the American Thoracic Society|March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatmentCraig M Hales, Charles M Heilig, Richard Chaisson, et al.
Contemporary Clinical Trials|April 2, 2023
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentineNigel A Scott, Claire Sadowski, Andrew Vernon, et al.
Lancet (London, England)|September 21, 2002
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialDebra Benator, Mondira Bhattacharya, Lorna Bozeman, et al.
Annals of the American Thoracic Society|February 3, 2018
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere TrialsRuth N Moro, Nigel A Scott, Andrew Vernon, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|May 2, 2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman, John L Johnson, Stefan Goldberg, et al.
Pageof 6